World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
29610
World Ranking
16950
National Ranking
638

Peter J. M. Valk publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Peter J. M. Valk sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 321 publications — 21st percentile

21% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Peter J. M. Valk D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Peter J. M. Valk sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Peter J. M. Valk is affiliated with Erasmus University Rotterdam in the Netherlands. Their research primarily centers on hematology, with a significant focus on acute myeloid leukemia (AML) and related hematological malignancies. Valk has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology.

Valk's publication record includes a strong emphasis on acute myeloid leukemia research, as shown by key papers such as:

  • "2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party" (2021, Blood)
  • "Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome" (2022, Blood)
  • "Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia" (2020, Science Translational Medicine)
  • "CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome" (2021, Blood)
  • "TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML" (2020, Blood Advances)

These publications reflect involvement in topics such as cancer genomics, diagnostics, chemotherapy resistance, immunotherapy response, and genetic mutations influencing AML outcomes.

Frequent coauthors who have collaborated with Valk include:

  • Bob Löwenberg
  • Gert J. Ossenkoppele
  • François G. Kavelaars
  • Jacqueline Cloos
  • Melissa Rijken

Valk's work has appeared predominantly in these scientific venues:

  • Blood (37 publications)
  • HemaSphere (14 publications)
  • Blood Advances (11 publications)
  • Leukemia (11 publications)
  • Clinical Lymphoma Myeloma & Leukemia (10 publications)

The main fields of study they contribute to encompass:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields reflecting the focus of Valk's research include:

  • Hematology
  • Molecular Biology
  • Genetics
  • Cancer Research
  • Oncology

The principal topics of their work cover:

  • Acute Myeloid Leukemia Research
  • Cancer Genomics and Diagnostics
  • Chronic Myeloid Leukemia Treatments
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Histone Deacetylase Inhibitors Research
  • Acute Lymphoblastic Leukemia Research
  • Retinoids in leukemia and cellular processes

Best Publications

  • Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

    Maria E. Figueroa;Omar Abdel-Wahab;Chao Lu;Patrick S. Ward

  • Prognostically useful gene-expression profiles in acute myeloid leukemia.

    Peter J.M. Valk;Roel G.W. Verhaak;M. Antoinette Beijen;Claudia A.J. Erpelinck

  • DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia

    Maria E. Figueroa;Sanne Lugthart;Yushan Li;Claudia Erpelinck-Verschueren

  • Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): Association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance

    Roel G. W. Verhaak;Chantal S. Goudswaard;Wim van Putten;Maarten A. Bijl

  • A 17-gene stemness score for rapid determination of risk in acute leukaemia

    Stanley W. K. Ng;Amanda Mitchell;James A. Kennedy;James A. Kennedy;James A. Kennedy;Weihsu C. Chen

  • Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome

    Bas J. Wouters;Bob Löwenberg;Claudia A. J. Erpelinck-Verschueren;Wim L. J. van Putten

  • Molecular Minimal Residual Disease in Acute Myeloid Leukemia

    Mojca Jongen-Lavrencic;Tim Grob;Diana Hanekamp;François G Kavelaars

  • A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia

    Stefan Gröschel;Stefan Gröschel;Mathijs A Sanders;Remco Hoogenboezem;Elzo de Wit

  • MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia.

    Mojca Jongen-Lavrencic;Su Ming Sun;Menno K. Dijkstra;Peter J. M. Valk

  • High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study

    Monique Terwijn;Wim L J van Putten;Angèle Kelder;Vincent H J van der Velden

  • Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity

    Erdogan Taskesen;Lars Bullinger;Andrea Corbacioglu;Mathijs A. Sanders

  • 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document.

    Michael Heuser;Sylvie D Freeman;Gert J Ossenkoppele;Francesco Buccisano

  • Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

    Saman Abbas;Sanne Lugthart;François G. Kavelaars;Anita Schelen

  • Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling

    Roel G.W. Verhaak;Bas J. Wouters;Claudia A.J. Erpelinck;Saman Abbas

  • Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias.

    Rory S. Care;Peter J. M. Valk;Anne C. Goodeve;Faisel M. Abu-Duhier

  • Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia

    Sheng Li;Francine E Garrett-Bakelman;Stephen S Chung;Mathijs A Sanders

  • High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients.

    Sahar Barjesteh van Waalwijk van Doorn-Khosrovani;Claudia Erpelinck;Wim L. J. van Putten;Peter J. M. Valk

  • Tel/Etv6 is an essential and selective regulator of adult hematopoietic stem cell survival

    Hanno Hock;Eliza Meade;Sarah Medeiros;Jeffrey W. Schindler

  • Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

    Barjesteh van Waalwijk van Doorn-Khosrovani S;Erpelinck C;Meijer J;van Oosterhoud S

  • High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

    Sanne Lugthart;Ellen van Drunen;Yvette van Norden;Antoinette van Hoven

Frequent Co-Authors

Bob Löwenberg
Bob Löwenberg Erasmus MC
Ruud Delwel
Ruud Delwel Erasmus MC
Konstanze Döhner
Konstanze Döhner University of Ulm
Lars Bullinger
Lars Bullinger Charité - University Medicine Berlin
Ari Melnick
Ari Melnick Cornell University
Jan J. Cornelissen
Jan J. Cornelissen Erasmus University Rotterdam
Gert J. Ossenkoppele
Gert J. Ossenkoppele University of Amsterdam
Arnold Ganser
Arnold Ganser Hannover Medical School
Hartmut Döhner
Hartmut Döhner University of Ulm
H. Berna Beverloo
H. Berna Beverloo Erasmus University Rotterdam

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those exploring alternative routes or supplementary qualifications in healthcare, a variety of affordable online options are available. Pursuing an online health information management degree can prepare you for behind-the-scenes roles managing patient data and health records, critical for the smooth operation of medical facilities.

If you’re interested in the administrative side of healthcare, consider enrolling in one of the cheapest medical billing and coding online courses. These programs offer a quick pathway into an in-demand career working with insurance and patient billing processes.

For those who wish to advance their clinical careers, the most affordable nurse practitioner programs provide a flexible path to becoming a licensed NP, opening doors to higher responsibilities and salary.

Additionally, students with a non-nursing bachelor’s can fast-track their careers with the cheapest online accelerated bsn programs. These degrees allow for quick entry into nursing, meeting the growing demand for skilled professionals across the US.

Best Scientists Citing Peter J. M. Valk

Trending Scientists

Recently Published Articles